A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
Approach to the Initial Treatment of Older Patients with Mantle Cell Lymphoma
2020
Hematology/Oncology Clinics of North America
Preserved Fulltext
With a median age of 65 years, mantle cell lymphoma affects predominantly older patients with comorbidities. Initial treatment of older patients is not standardized but traditionally includes chemoimmunotherapy regimens that are not curative. Incorporation of maintenance strategy after induction and introduction of novel agents have expanded access to effective treatment options and improved survival outcome. Ongoing randomized studies comparing induction regimens and maintenance strategies are
doi:10.1016/j.hoc.2020.06.005
pmid:32861284
fatcat:v27drwmscjdhdffi7utmxusdyu